Tipiracil (CAS No 183204-74-2) is a thymidine phosphorylase inhibitor primarily studied in the context of cancer research It originates from the development of combination therapies aimed at enhancing the efficacy of chemotherapeutic agents Tipiracil functions by inhibiting the enzyme thymidine phosphorylase which is involved in nucleotide metabolism ultimately affecting tumor growth and angiogenesis Its common in vitro activity is observable in the nanomolar to low micromolar range making it effective in various biochemical assays and cellular models In research applications Tipiracil is frequently used in combination with other drugs like trifluridine in cell culture studies animal models and preclinical drug screenings to assess antitumor potential Experimental concentrations typically depend on the specific research design allowing for flexibility in dosing strategies to fit the research aim